The UK's e-Therapeutics plc has become the latest biotech to quit the London Stock Exchange’s Alternative Investment Market (AIM), with CEO Ali Mortazavi slamming the lack of risk the country's investors are prepared to take on to support the sector.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?